Qiagen partners with NeuMoDx on PCR systems with option to acquire for $234M

Qiagen will commercialize NeuMoDx's PCR-based molecular diagnostic systems outside the U.S. and has an option to acquire all NeuMoDx shares not already owned for approximately $234 million, contingent on milestones.

“The partnership allows Qiagen to acquire all NeuMoDx shares not currently owned by Qiagen at a predetermined price of approximately $234 million.”insideprecisionmedicine.com

• 1 source
• insideprecisionmedicine.comQiagen Partners with NeuMoDx on PCR-Based MDx Systems, Future MergerInside Precision Medicine Staff WriterSep 17, 2018

Summarized from public sources; check the original articles before acting on it.